The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma.
The simple postabsorptive urine hydroxyproline (Spot-HYPRO) with dialyzable and non-dialyzable (ND) fractions was measured in 28 patients with multiple myeloma. Myeloma patients with bone disease had higher total Spot-HYPRO and dialyzable fractions (P less than 0.001) than myeloma patients without bone disease or controls. The ND fraction of the Spot-HYPRO was elevated in myeloma patients with renal disease as compared with myeloma patients without renal disease and controls (P less than 0.01). Follow-up studies of ten myeloma patients demonstrated a close correlation between Spot-HYPRO and the dialyzable fraction and the evolution of bone disease. The Spot-HYPRO and its dialyzable fraction constitute a simple, inexpensive, and accurate test for the diagnosis and follow-up of the skeletal disease in patients with multiple myeloma.
D001862:Bone Resorption / Q000150:complications* / Q000175:diagnosis; D003404:Creatinine / Q000097:blood; D003956:Dialysis; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D007674:Kidney Diseases / Q000150:complications / Q000652:urine; D009101:Multiple Myeloma / Q000150:complications* / Q000652:urine; D009367:Neoplasm Staging; D010014:Osteolysis / Q000175:diagnosis; D011336:Probability
D003404:Creatinine; D006909:Hydroxyproline